Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858295 | 0.86 | CHRM2 (0.32) | — | |
| SCHEMBL1859874 | 0.80 | MTNR1A (0.32) | MTNR1AMTNR1B | |
| SCHEMBL1858552 | 0.79 | MTNR1A (0.31) | MTNR1AMTNR1B | |
| SCHEMBL1856517 | 0.74 | MTNR1A (0.32) | MTNR1AMTNR1BKMT2A | |
| SCHEMBL1856340 | 0.70 | MTNR1A (0.34) | MTNR1AMTNR1B | |
| SCHEMBL67323 | 0.63 | MTNR1A (0.44) | MTNR1AMTNR1BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1860215 | 0.62 | MTNR1A (0.39) | MTNR1AMTNR1BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1400933 | 0.61 | MTNR1A (0.48) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL67116 | 0.60 | MTNR1A (0.45) | MTNR1AMTNR1BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31222331 | 0.58 | SMN1; SMN2 (0.47) | MTNR1AMTNR1BMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | MTNR1A 515/4885MTNR1B 605/4885MEN1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.